Transcriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Open Access
- 19 October 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Abstract
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.Keywords
Funding Information
- National Natural Science Foundation of China (82341213)
- National Natural Science Foundation of China (82570278)
This publication has 48 references indexed in Scilit:
- Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy EraCurrent Hematologic Malignancy Reports, 2026
- Strategies to Enhance CAR ‐T Cell Persistence in Hematologic Malignancies: From Molecular Design to Clinical OptimizationAmerican Journal of Hematology, 2025
- Acute lymphocytic leukaemiaThe Lancet, 2025
- CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaCancer Cell, 2025
- Myeloid effector cells in cancerCancer Cell, 2024
- Bone marrow fibrosis is associated with non‐response to CD19 CAR T‐cell therapy in B‐acute lymphoblastic leukemiaAmerican Journal of Hematology, 2023
- Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemiaMolecular Therapy, 2021
- Immune-Based Therapies in Acute LeukemiaTrends in Cancer, 2019
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015